2 Information about dabrafenib plus trametinib

Marketing authorisation indication

2.1 Dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) is indicated for 'the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for dabrafenib.


2.3 Dabrafenib costs £1,400 per 28‑pack of 75 mg capsules and trametinib costs £4,800 per 30‑pack of 2 mg tablets (excluding VAT; BNF online accessed February 2023).

2.4 The company has a commercial arrangement. This makes dabrafenib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)